Osteosarcopenia (OSA) affects 5-37% of community-dwelling older people (≥65 years) and is diagnosed at even higher rates in people with lowenergy trauma (osteoporotic) bone fractures (7.1–96.3%). There are no diagnostic biochemical markers available and no approved pharmacological agents for treatment of sarcopenia so far. With the present project, we aim t...

01. October 2022 - 30. September 2025 | 3.07 Medical sciences/Metabolic and hormonal disorders

Comprehensive characterization of GWAS hits – pipeline to novel drug targets for anabolic treatment of osteoporosis (GWASforAna)

Osteoporosis is the most common skeletal disease with deterioration of bone structure and increased risk of bone fractures. Even though the biology of osteoporosis has been well studied, effective personalized approach to prevention, diagnosis and particular anabolic drugs to prevent bone fractures are still lacking and there is an urgent need to identify novel targ...

01. July 2019 - 30. June 2022 | 3.07 Medical sciences/Metabolic and hormonal disorders

Identification of new expression regulators of RANKL, a key molecule not only in bone remodelling

Receptor activator of nuclear factor-κB ligand (RANKL) is a part of the RANKL/RANK/OPG system which plays a crucial role in bone resorption and several other physiological processes. RANKL deregulation has been implicated in osteoporosis (OP), osteoarthritis (OA), autoimmune diseases, chronic inflammatory diseases and various cancers, leading to approval of de...

01. January 2016 - 31. December 2018 | 3.07 Medical sciences/Metabolic and hormonal disorders